Abbreviations: DAAs, direct-acting antiviral agents; NI, nucleotide inhibitor; PI, protease inhibitor; RAS, resistance-associated substitution; SVR, sustained virologic response; SVR12, sustained virologic response 12 weeks after treatment. 
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Methods:
We analyzed data from 2144 participants in phase 2 and 3 studies of patients with HCV genotype 1a or b infection received the combination of ledipasvir (90 mg) and sofosbuvir (400 mg) (ledipasvir/sofosbuvir) once daily, with or without ribavirin twice daily. Population and/or deep sequence analyses of the HCV NS3, NS5A, and NS5B genes were performed on blood samples collected at baseline.
Results: Overall, 16.0% of patients had detectable baseline RASs in NS5A. Among patients with HCV genotype 1b infection, there was no significant effect of baseline RASs in NS5A on sustained viral response 12 weeks after the end of treatment (SVR12) with ledipasvir/sofosbuvir and only a small effect in patients with HCV genotype 1a infection. RASs in NS5A that increased the half maximal effective concentration 50 to ledipasvir by more than 100-fold (Q30H/R, L31M in genotype 1a HCV, and Y93H) reduced the rate of SVR12 in treatment-naïve patients given ledipasvir/sofosbuvir for 8 weeks, (P=.011), but not 12 weeks. These same baseline NS5A RASs reduced the percentage of treatment-experienced patients who achieved an SVR12 to 12 weeks (but not 24 weeks) ledipasvir/sofosbuvir (P<.001). These RASs had a small effect in patients given ledipasvir/sofosbuvir in combination with ribavirin for 12 weeks. Overall, 2.5% of patients had baseline NS5B nucleotide inhibitor RASs (L159F, N142T, S282G, or
Introduction
Development of direct-acting antivirals (DAAs) in recent years has dramatically enhanced sustained virologic response (SVR) rates in HCV genotype 1 chronic infected patients. 1 In the Phase 3 ION-1, ION-2, and ION-3 studies [2] [3] [4] , and the Phase 2 LONESTAR study 5 , treatment naïve and experienced HCV genotype 1 infected patients with and without liver cirrhosis who received 8, 12 or 24 weeks of the fixed dose combination of NS5A inhibitor ledipasvir 6 and the nucleoside analog sofosbuvir (ledipasvir/sofosbuvir) with or without ribavirin achieved SVR rates of 94 percent to 99 percent.
Despite these high SVR12 rates, because the high-rate replication and poor fidelity of the HCV RNA-dependent polymerase leads to heterogeneous virus populations in infected patients, it is possible that the subpopulation of patients with pre-existing mutations that confer in vitro resistance to sofosbuvir or ledipasvir may influence outcome. 7 Such pre-existing mutations may exist at low levels in untreated patients, and emerge under the selective pressure of DAAs. 7, 8 For ledipasvir, in vitro and in vivo resistance are primarily associated with substitutions at genotype 1a residues K24, M28, Q30, L31, P32, H58 and Y93 and genotype 1b residues L31, P58, A92 and Y93. 9, 10 Resistance to sofosbuvir is conferred by the S282T substitution in NS5B. 11 S282T was first described as the major resistance-associated substitution (RAS) for other nucleotide inhibitors (NIs). 12 In addition, the combination of S96T and N142T has been observed following in vitro selection with the NI R1479. 13 M289I/L/V were selected in vitro by various NIs, 11, 13 and a combination of L159F and L320F was observed in 1 patient who had a partial response during treatment with mericitabine. 14, 15 A comprehensive analysis of all substitutions in NS5B among all sofosbuvir-treated patients in the Phase 2 and 3 studies M A N U S C R I P T
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8 identified 2 treatment-emergent substitutions, L159F and V321A, using deep sequencing (cutoff 1 percent). 15, 16 The impact of HCV baseline RASs on SVR may depend on the susceptibility/fitness of the RASs, the patient population, the specific regimen and treatment duration. Pre-existing RASs clearly influence virologic outcomes for the combination of the PI asunaprevir with the NS5A inhibitor daclatasvir, which is an approved treatment in Japan. While the overall SVR rate in the pivotal trial was 84 percent, the SVR rates for patients with baseline L31 or Y93 substitutions were between 38-41 percent. 19 In contrast, there was no apparent impact of baseline NS5A RASs on virologic response in patients treated with sofosbuvir + daclatasvir in a small Phase 2b study. 20 These results, however, may have been a consequence of the small number of patients who relapsed, limiting the ability to evaluate the impact of NS5A
RASs on outcome.
In this analysis, the baseline prevalence and effects of NS5A inhibitor, NI, and PI RASs on virologic response to ledipasvir and sofosbuvir with and without ribavirin in a large number of patients (n=2144) from multiple studies from the ledipasvir/sofosbuvir Phase 2/3 development program were investigated.
Methods
Ethics statement
All studies were conducted in accordance with the Declaration of Helsinki, Good Clinical
Practice guidelines, and local regulatory requirements. All patients provided written informed consent.
Study design
Detailed descriptions of studies ION-1 (n=865), ION-2 (n=440), ION-3 (n=647), LONESTAR (n=100), and ELECTRON (n=92) have been published [2] [3] [4] [5] 21 and are described briefly below. 
Sequencing analyses
Resistance testing was performed on available baseline plasma samples with HCV RNA ≥1000 IU/mL. For the NS5A gene, at the beginning of the studies only population sequencing was 
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Substitutions are reported as differences compared with a genotype-specific reference strain:
genotype 1b Con1 (AJ238799); genotype 1a H77 (Genbank accession number NC_004102). 
Drug susceptibility analyses
Resistance mutations were introduced into the genotype 1a or genotype 1b replicon by sitedirected mutagenesis and tested in transient transfections as previously described. 23 Briefly, NS5A mutations were introduced into a plasmid encoding the PI-hRluc replicon using a QuikChange II XL mutagenesis kit, following the manufacturer's instructions (Stratagene, La Jolla, CA). Mutations were confirmed by DNA sequencing. Replicon RNAs were transcribed in vitro from replicon-encoding plasmids using a MEGAscript kit (Ambion, Austin, TX). RNA was transfected into Huh-lunet cells using the method of Lohmann et al. 24 Briefly, cells were trypsinized and washed twice with PBS. A suspension of cells was mixed with RNA and subjected to electroporation. Cells were transferred into 40 ml of pre-warmed culture medium and then seeded into 96-well plates (100 µL/well). Compounds were diluted in 100 percent DMSO and added to cells. Cells were treated for 3 days, after which culture media were removed, cells were lysed, and Renilla luciferase activity was quantified using a commercially 
Treatment outcomes by level of RAS resistance and Prior Treatment Status
NS5A
RASs were classified by level of resistance to ledipasvir (Table 1) . Patients with NS5A
RASs were classified according to their prior treatment status. Among treatment-naïve genotype 1 patients in the ledipasvir/sofosbuvir group, 102/887 (11.5 percent) had at least 1 RAS that conferred >100-fold-resistance to ledipasvir. A significant reduction in the SVR rate (Figure 2a) was seen among treatment-naive patients with NS5A RASs conferring >100-fold ledipasvir resistance who received only 8 weeks of ledipasvir/sofosbuvir therapy (82.8 percent; p=0.011).
A significant reduction in SVR based on the presence of high-level baseline NS5A RASs was not observed among treatment-naïve patients treated for 12 or 24 weeks with ledipasvir/sofosbuvir, and all patients with NS5A RASs conferring <100-fold ledipasvir resistance achieved SVR12. Furthermore, of the 5 patients who did not achieve SVR12 after 8 weeks of ledipasvir/sofosbuvir therapy, 3 had high (>6 million IU/ml) HCV RNA levels at baseline and 3 had at least one NS5A RAS conferring >100-fold-resistance to ledipasvir at a frequency of >15 percent at baseline (Table 1 ). Similar SVR rates (82.1 percent) were observed for treatment-naïve patients with NS5A RASs conferring >100-fold ledipasvir resistance who percent; 113/116) or those with high-level RASs treated for 24 weeks (100 percent; 6/6). Of the 6 patients with RASs who did not achieve SVR12 after 12 weeks of treatment, all had at least one RAS conferring >100-fold-resistance to ledipasvir at a frequency of >15 percent at baseline and 4 had multiple high-level NS5A RASs (Table 1 ).
Relative to 100 percent SVR for 24 weeks of ledipasvir/sofosbuvir treatment shown in Figure 2b , reduced SVR rates (81.8 percent) were also observed among treatment-experienced patients with NS5A RASs conferring >100-fold ledipasvir resistance who received 12 weeks of ledipasvir/sofosbuvir+ribavirin therapy ( Figure 2c) ; however, the overall SVR rate was numerically higher than that observed for 12 weeks of ledipasvir/sofosbuvir without ribavirin (64.7 percent). No significant differences were observed among treatment-naïve or treatmentexperienced patients with NS5A RASs conferring >100-fold ledipasvir resistance who received ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks (treatment-naïve) or 24 weeks (treatment-experienced) (Figure 2c ).
Prevalence and geographical distribution of specific NS5A RASs
The prevalence of specific ledipasvir RASs detected at baseline was evaluated using different 
Relationship of specific substitution and treatment outcome
The relationship of baseline NS5A RASs to the treatment outcome in patients treated with ledipasvir/sofosbuvir was evaluated for the most common NS5A RASs: K24R, M28T, Q30H, Q30R, L31M, and Y93H. The SVR rates ranged from 80-93.3 percent and 75-88.2 percent for M A N U S C R I P T
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NS5A RASs that confer >100-fold-resistance to ledipasvir (Q30H, Q30R, L31M in genotype 1a
and Y93H) using 1 percent and 15 percent deep sequencing cutoffs, respectively (Figure 4a ).
Slightly lower SVR rates were observed using the 15 percent cutoff compared to the 1 percent cutoff for these RASs. For K24R, which confers 3.7-fold resistance to ledipasvir, the SVR rate was 100 percent independent of deep sequencing cutoff. For M28T, which confers 61-fold resistance to ledipasvir, the SVR rate was also reduced, however the 2 patients with virologic failure with M28T also had other NS5A RASs conferring >100-fold resistance (Table 1 ). In the case of L31M, reduced SVR rates were only observed in patients with genotype 1a infection, consistent with only 3.4-fold reduced susceptibility for this RAS in the background of genotype 1b.
Overall, the relapse rate increased with the number of RASs. Of patients with no baseline RAS, and Q30 and virologic failure, many patients with these substitutions and the same mutant viral load achieved SVR12 and overall there was no significant effect.
Baseline NS5B NI substitutions
Baseline NS5B sequencing was attempted for a subset of patients from the ION-1 study and all patients from the LONESTAR, ELECTRON, ION-2, and ION-3 studies. Successful NS5B sequencing was obtained for 1692 patients (1291 genotype 1a and 395 genotype 1b, 6 other), including deep sequencing results from 1628 patients. The NS5B RAS S282T was not detected in any patient using a 1 percent cutoff for deep sequencing (Table 2) . A total of 41 sequenced patients had other NI RASs at baseline (36 with L159F and 5 with N142T); all 41 of these patients achieved SVR12 (Table 2 ). In addition 1 patient had S282G and another patient had L320S, two substitutions at two residues associated with NI resistance; both patients achieved SVR12. Among treatment-experienced patients, a lower SVR12 rate was observed for those who had baseline NS5A RASs associated with >100-fold-resistance to ledipasvir and were treated for 12 weeks without ribavirin. Six out of these 17 patients did not achieve SVR12. Of these 6 patients,
Baseline NS3 substitutions
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23 all had at least one NS5A RAS conferring >100-fold-resistance to ledipasvir at a frequency of >15 percent at baseline and 4/6 had multiple high-level ledipasvir RASs. Treatment-experienced genotype 1a patients with pre-existing NS5A RASs that confer a >100 fold resistance to ledipasvir represented 6.9 percent (17/245) of the patients in this analysis. However, as recommended by treatment guidelines, all treatment-experienced patients with baseline RASs treated for 24 weeks with ledipasvir/sofosbuvir achieved SVR12.
The addition of ribavirin to 12 weeks of ledipasvir/sofosbuvir resulted in an improved SVR12 rate in treatment-experienced patients with NS5A RASs associated with >100-fold-resistance to ledipasvir, relative to 12 weeks of ledipasvir/sofosbuvir without ribavirin; however, the SVR12 rate was still numerically lower than that observed with 24 weeks of therapy. This observation stands in contrast to data from the SIRIUS trial 27 , in which treatment-experienced cirrhotic patients, were randomized to 24 weeks of ledipasvir/sofosbuvir or 12 weeks of ledipasvir/sofosbuvir+ribavirin. All the patients (8/8) with NS5A RASs conferring >100-foldresistance to ledipasvir treated for 12 weeks with ledipasvir/sofosbuvir+ribavirin achieved SVR12; conversely, 7/9 (78 percent) of patients with NS5A RASs conferring >100-foldresistance to ledipasvir treated for 24 weeks with ledipasvir/sofosbuvir achieved SVR12. These data suggest that for treatment-experienced patients with NS5A RASs, 12 weeks of ledipasvir/sofosbuvir+ribavirin provides similar effectiveness compared to ledipasvir/sofosbuvir for 24 weeks.
For the specific NS5A RASs Q30H/R, L31M in genotype 1a and Y93H that confer >100-foldresistance to ledipasvir, SVR rates ranged from 80-93.3 percent and 75-88.2 using 1 and 15 percent deep sequencing cutoffs, respectively. Overall, slightly lower SVR rates were observed using the 15 percent cutoff compared to the 1 percent cutoff. The number of RASs harbored M A N U S C R I P T
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within the virus seems to be a predictor of treatment failure. An increasing rate of virologic relapse was observed in patients without baseline NS5A RASs (1.6 percent) to patients with 1, 2 or at least 3 RASs (4.9, 10.2 and 15.8 percent, respectively). However, the prevalence of patients with 1, 2 or at least 3 pre-existing NS5A RASs decreased from 12.6 percent to 2.3 percent and 0.9 percent. This observation is in line with a higher relapse rate observed in patients who received sofosbuvir plus ledipasvir after failure to a ledipasvir-containing regimen and the presence of multiple NS5A RASs. 28 Baseline NS3 RASs were detected in 53.2 percent of patients who were previously treated with PI-containing regimens, of whom 98.6 percent achieved SVR12. Additionally, Q80
polymorphisms were observed in 46.0 percent of PI treatment-naïve patients and 41.5 percent of PI treatment-experienced patients, of whom 96.8 percent and 97.3 percent patients achieved SVR12, respectively. Taken together, no association between any NS3 RAS and treatment outcome was observed in patients treated with ledipasvir/sofosbuvir, which is consistent with the lack of cross resistance between PIs and either ledipasvir or sofosbuvir in vitro. In addition, the NS5B NI RAS S282T was not detected in any patient at baseline. Of the 2.5 percent of patients with other NI RASs at baseline, all achieved SVR12, including 1 patient with S282G.
In summary, high SVR rates were achieved in the presence of baseline HCV NS5A RASs upon treatment with ledipasvir/sofosbuvir in the majority of patient populations. NS5A RASs corresponding to >100-fold-resistance to ledipasvir together with a shortened treatment duration of 8 weeks in treatment-naïve patients or 12 weeks in treatment-experienced patients, were associated with reduced SVR rates. Most of these patients were not treated according to current treatment guidelines. In the majority of these patients, at least one NS5A RAS conferring >100-fold-resistance to ledipasvir was detected at a frequency of >15 percent at baseline, which could M A N U S C R I P T 
A C C E P T E D ACCEPTED MANUSCRIPT
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
